Dabaz 500 Mg Infusion 50 Ml

• Malignant melanoma: This skin cancer begins in pigment-producing cells, and dacarbazine can slow or destroy abnormal cells as part of specialist treatment.
• Hodgkin's disease: This cancer affects the lymphatic system, and dacarbazine is used in selected chemotherapy treatment plans.

• Nausea: Dacarbazine can upset the stomach during or after an infusion. Tell your care team if nausea prevents you from eating or drinking.
• Vomiting: Treatment may trigger vomiting soon after it is given. Report repeated vomiting or inability to keep fluids down so supportive care can be arranged.
• Decreased appetite: Treatment may reduce hunger and make eating difficult. Tell your care team if you cannot maintain food or fluid intake.
• Low blood counts: Bone marrow suppression can lower red cells, white cells and platelets, causing tiredness, infection risk or bruising. Report fever, bleeding or marked weakness urgently.

Other General Warnings

• If you have any liver disease.
• If you have a history of bone marrow problems or low blood counts.
• If you are due to have any vaccinations.
• If you have kidney problems.
• If you are taking medicines that can suppress bone marrow function.

• Keep every blood-test and treatment appointment arranged by your cancer team.
• Report fever, chills, unusual bruising, bleeding or severe weakness promptly.
• Drink fluids as advised if nausea or vomiting makes eating difficult.
• Avoid people with infections and check before receiving any vaccine.
• Tell your care team about mouth sores, persistent vomiting or pain at the infusion site.

Overdose

Missed a Dose

Interactions with other medicines

Interactions with food items